scholarly journals Chemotherapeutic Effects on Hematopoiesis: A Mathematical Model

1998 ◽  
Vol 1 (3) ◽  
pp. 209-221 ◽  
Author(s):  
John Carl Panetta

Blood cell production is one of the major limiting effects of cell-cycle-specific chemotherapy. By studying the effects of the drugs on a mathematical model of hematopoiesis, a better understanding of how to prevent over-reduction of circulating blood may be investigated.In this model we will use a delay-differential equation developed by Mackey and Glass (1977) to show acceptable chemotherapeutic deses (i.e. survival of the circulating blood cells) as a function of: the period which the drugs are administered; the strength of the dose; and the delay from initiation of blood cell production to its release into the blood stream. We then make qualitative comparisons to know effects of cell-cycle-specific chemotherapy on circulating blood cell elements. Finally, we also consider how the effects of hematopoietic growth factors alter the outcome of the therapy.

Physiology ◽  
1993 ◽  
Vol 8 (4) ◽  
pp. 170-174
Author(s):  
MJ Koury ◽  
MC Bondurant

Hematopoietic growth factors have been thought to control blood cell production by stimulating proliferation and differentiation of hematopoietic progenitor cells. However, recent studies show that these growth factors prevent programmed death in progenitor cells. A model of hematopoiesis based on prevention of this death by hematopoietic growth factors is presented.


Blood ◽  
1979 ◽  
Vol 53 (1) ◽  
pp. 157-165 ◽  
Author(s):  
MJ Cline ◽  
DW Golde

Abstract The development since 1966 of a technology for growing stem cells in vitro has provided new insights into the controls of blood cell production. Hematopoietic hormones have been purified and important cellular interactions in hematopoiesis have been defined.


Blood ◽  
2020 ◽  
Vol 136 (Supplement 1) ◽  
pp. 34-35
Author(s):  
Christopher Thom ◽  
Chintan Jobaliya ◽  
Benjamin F Voight ◽  
Stella P Chou ◽  
Deborah L French

Donor-derived blood transfusions are critical to our healthcare system, but do not fully meet the needs of patients with multiple alloantibodies, rare blood types, or HLA-sensitization. These needs have fueled the concept of ex vivo blood cell production, which might address issues related to demographic aging, infectious outbreaks transmitted by transfusions, and rare blood types. Blood cells produced in vitro could be used for transfusions, and could also be used as blood bank testing reagents (Coleman et al, Transfusion 2019). One major challenge in deploying this system is efficiently scaling up cell production. We used machine learning and genome-edited induced pluripotent stem cell (iPSC) models to determine that Tropomyosin 1 (TPM1) normally inhibits in vitro hematopoiesis. TPM1 knockout (TPM1KO) iPSCs produced 2-fold more hematopoietic progenitor cells (HPCs) than controls, thereby increasing production of mature blood cells that were functionally normal (Thom et al, BMC Biol 2020). During human hematopoiesis, HPCs arise from specialized vascular 'hemogenic endothelial' cells (HE) with distinct surface markers that can be used for identification and isolation. To define molecular mechanisms by which TPM1 regulates in vitro primitive hematopoiesis, we performed RNA sequencing analysis on sorted KDR+CD31+ endothelial cells and CD43+ HPCs from TPM1KO and control cultures. TPM1KO endothelial cells and HPCs had altered expression of genes and pathways known to regulate HE biology, including cell adhesion, integrin expression, and integrin-mediated signaling (p<0.05). 'Anoikis' is an apoptosis-like programmed cell death that occurs after extracellular matrix detachment. This process may limit nascent non-adherent HPC production in vitro, but has not been previously studied. TPM1KO cells showed increased expression of N-cadherin and RAP1-activating genes; increased N-cadherin and activated RAP1 limit anoikis in other biological contexts. In sum, these results suggested that TPM1KO cultures increased HE production and/or survival. To analyze HE production at the single cell level, we sorted KDR+CD31+CD43- endothelial cells and plated them in limiting dilution. We cultured sorted cells in hematopoietic cytokines for 7 days, and analyzed the number of wells in which CD43+ HPCs arose from sorted TPM1KO and control cells. Using limiting dilution analysis (Hu & Smyth,J. Immunol. Methods 2009), we found that TPM1KO cultures produced 2-fold more HE than controls. These results show that TPM1KO enhances in vitro hematopoiesis by increasing HE and subsequent HPC production, perhaps by limiting anoikis in nascent HPCs. TPM1-mediated regulation at the HE stage represents a novel mechanism that may be genetically or pharmacologically exploited to augment in vitro hematopoiesis. These findings will help boost in vitro HPC and blood cell production to clinically relevant scales, supporting efforts to produce blood cells for direct transfusion and/or to be used as clinical screening reagents. Disclosures No relevant conflicts of interest to declare.


Blood ◽  
2010 ◽  
Vol 116 (21) ◽  
pp. SCI-41-SCI-41
Author(s):  
Douglas J. Hilton

Abstract Abstract SCI-41 Our current research takes genetic, genomic and bioinformatic approaches to identify gene networks important in regulating haemopoiesis; the production of nine lineages of blood cells from multipotential, self-renewing stem cells. In this presentation I will discuss our unpublished experiments aimed at elucidating pathways that regulate megakaryocyte-lineage commitment. Disclosures: Hilton: CSL: Research Funding; Murigen: Equity Ownership.


Author(s):  
P. Auger ◽  
Arnaud Ducrot

The aim of this paper is to provide a new mathematical model for a fishery by including a stock variable for the resource. This model takes the form of an infinite delay differential equation. It is mathematically studied and a bifurcation analysis of the steady states is fulfilled. Depending on the different parameters of the problem, we show that Hopf bifurcation may occur leading to oscillating behaviours of the system. The mathematical results are finally discussed.


2008 ◽  
Vol 03 (01n02) ◽  
pp. 125-133 ◽  
Author(s):  
JORGE C. LUCERO

This article analyzes a mathematical model for some aeroelastic oscillators in physiology, based on a previous representation for the vocal folds at phonation. The model characterizes the oscillation as superficial wave propagating through the tissues in the direction of the flow, and consists of a functional differential equation with advanced and delay arguments. The analysis shows that the oscillation occurs at a Hopf bifurcation, at which the energy absorbed from the flow overcomes the energy dissipated in the tissues. The bifurcation value of the flow pressure increases linearly with the tissue damping and the oscillation frequency. Also, it is minimum when the phase delay of the superficial wave to travel along the tissues is π, and increases indefinitely when the delay tends to 0 and to 2π.


Blood ◽  
2018 ◽  
Vol 132 (Supplement 1) ◽  
pp. 531-531
Author(s):  
Erik L. Bao ◽  
Jacob C. Ulirsch ◽  
Caleb A. Lareau ◽  
Leif S. Ludwig ◽  
Michael H. Guo ◽  
...  

Abstract Hematopoiesis is a well-characterized paradigm of cellular differentiation that is highly regulated to ensure balanced proportions of mature blood cells. However, many aspects of this process remain poorly understood in humans. For example, there is extensive variation in commonly measured blood cell traits, which can manifest as diseases at extreme ends of the spectrum, yet the vast majority of genetic loci responsible for driving these differences are currently unknown. Here, we integrate fine-mapped population genetics with high-resolution chromatin landscapes to gain novel insights into regulatory mechanisms critical for human blood cell production and disease. First, we conducted a genome-wide association study in 115,000 individuals from the UK Biobank, measuring the effects of genetic variation on 16 blood traits spanning 7 hematopoietic lineages (erythroid, platelet, lymphocyte, monocyte, neutrophil, eosinophil, basophil). Within each region of association (n = 2,056), we performed Bayesian fine-mapping on all common variants to resolve the most likely causal hits. Going further, we were interested in whether genetic variants predominantly act in terminal cell states or less differentiated progenitors. To this end, we overlapped fine-mapped variants with chromatin accessibility profiles (ATAC-seq) of 18 primary hematopoietic populations sorted from healthy donors. Across all lineages, 21% of regulatory variants were restricted to accessible chromatin (AC) peaks in terminal progenitors. Interestingly, 59% of variants fell in AC regions of one or more upstream progenitor states, suggesting that a significant amount of variation in blood traits stems from regulatory signaling in earlier stages of hematopoiesis. Motivated by this finding, we hypothesized that different branches of hematopoiesis (e.g., monocyte and red blood cell count) could be co-regulated by pleiotropic variants acting in common progenitor populations. Therefore, we investigated variants associated with 2 or more of the 7 blood cell types for which phenotypes were available. Remarkably, across 172 such variants, there was an average of 60% more open chromatin in progenitors than terminal cell types (mean 4.01 vs. 2.44 counts per million; p = 0.025). Examining the directional effects of these variants on distinct lineages, we discovered that 91% of pleiotropic variants exhibited a tune mechanism by changing the levels of different blood cells in the same direction. One such example was rs17758695 located in intron 1 of BCL2, an anti-apoptotic protein known to regulate cell death similarly across multiple hematopoietic cell types. In contrast, the remaining 9% of pleiotropic variants favored one lineage at the expense of others (switch mechanism), including novel variants near key myeloid-determining transcription factors CEBPA and MYC (rs78744187 and rs562240450). Together, these results suggest that pleiotropic variants 1) preferentially act in common progenitor rather than terminal cell types, and 2) predominantly tune multiple traits in the same direction, but may favor one at the expense of others when influencing lineage commitment. Finally, given the enrichment of fine-mapped variants in common progenitor states, we set out to determine whether classically defined hematopoietic populations could be divided into lineage-biased subpopulations based on differential genetic regulation of blood traits. To do so, we measured the enrichment of fine-mapped variants in the chromatin landscapes of 2,034 single cells isolated from 8 hematopoietic progenitor populations. Strikingly, we discovered significant heterogeneity within the common myeloid progenitor (CMP) population, in which one subset of cells exhibited greater open-chromatin enrichment for myeloid trait variants and relevant transcription factor (TF) binding (CEBPA, IRF8), whereas the other subset showed enrichment for erythroid trait variants and TFs (GATA1, KLF1). By integrating genetic fine-mapping with chromatin data, we identified hundreds of causal variants regulating 16 blood traits, characterized novel mechanisms of pleiotropic effects, and discovered cell states enriched for blood trait regulation. These findings provide new insights into the importance of genetic regulation in progenitor cell states and will contribute to knowledge of how these processes go awry in diseases of blood cell production. Disclosures No relevant conflicts of interest to declare.


Blood ◽  
2018 ◽  
Vol 132 (Supplement 1) ◽  
pp. 3835-3835
Author(s):  
Walatta-Tseyon Mesquitta ◽  
Hyunjun Kang ◽  
Matthew Wandsnider ◽  
Vera Brok-Volchanskaya ◽  
Kran Suknuntha ◽  
...  

Abstract Human pluripotent stem cell (hPSCs) have created alternative platforms for producing blood cells for transfusion, immunotherapies, and transplantation. Advancing blood cell manufacturing from hPSCs and translating hPSC-based technologies to the clinic requires improving the scalabilty of blood cell production through enhancing hematopoietic differentiation from hPSCs, and increasing expansion of lineage committed hematopoietic progenitors. The pyrimido-indole derivative UM171 has been described as one the most potent small molecules agonists for HSC expansion in vitro. However, the effect and mechanism of UM171 action on hPSC-derived hematopoietic progenitors (HPs) has not been explored. It also remains unclear whether UM171 selectively expands the most primitive multipotential HPs with lin-CD34+CD43+HSC phenotype, or affects progenitors already committed to a particular hematopoietic cell lineage. In our studies, we evaluated the effect of UM171 on the expansion and differentiation of CD34+CD43+HPs that were generated in chemically defined, serum- and feeder-free conditions from hPSCs. We revealed that culture of hPSC-derived HPs in HSC expansion conditions (SFEM with added TPO, SCF, FLT3, IL3 and IL6) in the presence of UM171 selectively expanded HPs with a unique CD34+CD41loCD45+phenotype. Isolation of this population by FACS revealed that it mostly possesses myeloid potential and is highly enriched in granulocytic progenitors (G-CFCs). In contrast, in lymphoid cultures on OP9-DLL4 in presence of SCF, Flt-3 and IL7, UM171 predominately expands CD34+CD7+CD41a-lymphoid progenitors with NK cell potential and increases up to 10-fold NK cell output in NK differentiation cultures. NK cells generated with UM171 possess strong cytotoxicity, express perforin and upregulate IFNg production, following stimulation with K562 or PMA. As determined by annexin V immunostaining, UM171 treatment decreased the number of apoptotic HPs in expansion cultures. In addition, UM171 expansion of HPs was associated with increased proliferation, as determined by BrdU assay and Ki67 staining. Extending these observations, cell cycle analysis revealed that UM171 predominantly increases the proportion of HPs in the early S phase of the cell cycle. These studies should improve our understanding of the effect of UM171 on de novo generated HPs and facilitate development of protocols for robust granulocyte and lymphoid cell production from hPSCs for adoptive immunotherapies. Disclosures Slukvin: Cynata Therapeutics Limited: Consultancy, Equity Ownership.


Blood ◽  
1979 ◽  
Vol 53 (1) ◽  
pp. 157-165 ◽  
Author(s):  
MJ Cline ◽  
DW Golde

The development since 1966 of a technology for growing stem cells in vitro has provided new insights into the controls of blood cell production. Hematopoietic hormones have been purified and important cellular interactions in hematopoiesis have been defined.


Sign in / Sign up

Export Citation Format

Share Document